WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn’t help patients with the deadly neurological condition.
Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription.
“While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS,” company co-founders said in a statement. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free.
The Food and Drug Administration approved the much-debated drug, Relyvrio, in September 2022, following a years-long advocacy campaign by patients with amyotrophic lateral sclerosis, or ALS.
Related articles:
Related suggestion:
Planning for potential presidential transition underway as Biden administration kicks it offHarvey Weinstein due back in court, while a key witness weighs whether to testify at a retrialKansas won't have legal medical pot, expand Medicaid for at least a yearAustralia's Grace Kim opens 4Giannis Antetokounmpo ruled out, Khris Middleton to start for Bucks against Pacers in Game 3Haniger hits grand slam in Mariners' 6Rory McIlroy and Shane Lowry remain tied for lead in the Zurich Classic of New OrleansSheriff's deputies fatally shoot driver while serving a highQueen Máxima of the Netherlands is a hit with the kids as she highJenifer Lewis reveals she was 'still on morphine' while performing on The Masked Singer after near
2.28s , 6500.2578125 kb
Copyright © 2024 Powered by Why Amylyx is pulling ALS drug Relyvrio from US market after study ,Culture Canvas news portal